TRELEGY ELLIPTA logo

Product menu

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long acting β2-agonist (LABA) or a combination of a LABA and a long-acting muscarinic antagonist (LAMA)3.

We are here to support

Request a demo device

Help your patients try the Ellipta device by ordering a demo device

Order a demo now

Speak to one of our experts

Do you want to know more? Request a visit or a call from your local representative.

Contact us here

Sign up for our updates

Sign up to receive email notifications on our latest webinars and more.

Sign up now

The burden of COPD

lung icon lung icon

There are around 1.4 million GP consultations per year due to COPD, and it is the second largest cause of emergency hospital admissions in the UK4

lung icon lung icon

Approximately 67% of COPD multiple inhaler triple therapy patients are juggling multiple device types5

Are you familiar with NICE and GOLD recommendations for your COPD patients who are not adequately controlled?

GOLD and NICE recommend classes of medicines, not specific products

Link leads to GSK adaptation of NICE COPD guidelines (2019) and the GOLD strategy report (2024)4,6

Click here

The most frequently reported adverse reactions observed with Trelegy, as reported in the Summary of Product Characteristics, are nasopharyngitis (7%), headache (5%) and upper respiratory tract infection (2%).In common with other ICS-containing medicines, there is an increased risk of pneumonia. Trelegy should be used with caution in patients with unstable or life-threatening cardiovascular disease. Please consult the SmPC for more information3

Abbreviations

NICE, National Institute for Health and Care Excellence; GOLD, Global Initiative for Chronic Obstructive Lung Disease.

References

  1. Van der Palen J; NPJ Primary Care Respiratory Medicine;2016;26:16079;1-8 
  2. Riley JH et al; International journal of chronic obstructive pulmonary disease;2016;11;1873-1880 
  3. Trelegy Ellipta, Summary of product characteristics.
  4. COPD in over 16s: diagnosis and management NICE guideline [NG115]. Last updated: July 2019.
  5. IQVIA Triple Dynamic Prescribing (DRx), Nov 2023, commissioned by GSK.
  6. GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2024 Report. https://goldcopd.org/2024-gold-report/.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to GSK on 0800 221 441 or UKSafety@gsk.com.

December 2024 | PM-GB-FVU-WCNT-240024 (V1.0)